BPC-157

Overview

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a partial sequence of human gastric juice protein BPC. It has a molecular weight of 1419.53 Da and a CAS number of 137525-51-0. BPC-157 is classified as a stable gastric pentadecapeptide because it resists hydrolysis by gastric acid and digestive enzymes, a property that differentiates it from most bioactive peptides and enables oral bioavailability in preclinical models. As of 2026, BPC-157 has been investigated in more than 90 published preclinical studies spanning models of gastrointestinal injury, tendon and ligament damage, nerve injury, wound healing, and organ protection. A complete review by Sikiric et al. (2011) established BPC-157 as a peptide with broad cytoprotective and regenerative properties across multiple organ systems. Subsequent work by Seiwerth et al. (2022) expanded the evidence base to include vascular protection and modulation of the nitric oxide (NO) system as a central integrative mechanism. BPC-157 is not approved by the United States Food and Drug Administration (FDA) for any therapeutic indication. It is classified under the World Anti-Doping Agency (WADA) Prohibited List category S0 (non-approved substances), making it banned in competitive sport. Despite the lack of regulatory approval, BPC-157 is widely used in the research peptide and biohacking communities, primarily administered via subcutaneous injection or oral capsule for musculoskeletal recovery and gut healing. Preclinical studies have demonstrated that BPC-157 accelerates healing of transected rat Achilles tendons, with treated animals showing superior biomechanical tendon strength at 14 days post-injury compared to controls (PMID: 30915550). In gastrointestinal models, BPC-157 has shown protective effects against NSAID-induced gastric lesions, ethanol-induced mucosal damage, and inflammatory bowel disease (IBD) analogs including experimentally induced colitis. The peptide has also demonstrated neuroprotective activity in dopaminergic and serotonergic systems, counteracting lesions caused by neurotoxins in rodent models. A 2025 pilot safety study by Lee et al. represents the first published human intravenous (IV) administration data for BPC-157. In this small cohort, IV BPC-157 was administered at escalating doses with no serious adverse events reported and no clinically significant changes in laboratory parameters (PMID: 40131143). While this study was not powered to establish efficacy, it provided the first formal human safety signal for the peptide. BPC-157 has also been shown to upregulate growth hormone receptor (GHR) expression in animal models, suggesting a possible synergistic effect when combined with growth hormone secretagogues. The peptide is typically supplied as a lyophilized powder requiring reconstitution with bacteriostatic water. Lyophilized BPC-157 should be stored at -20 degrees Celsius in a desiccated environment; once reconstituted, it should be refrigerated at 2-8 degrees Celsius and used within 28 days to maintain peptide integrity.

Potential Research Fields

Amino Acid Sequence

Contraindications

Research Disclaimer

This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.

$34.99

up to $79.99

$2.3330

7

15

vial, capsule

Sign in to leave a review

Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with BPC-157.

Tracking since Mar 13, 2026 · 13 data points

Price History

Featured Price

Latest test: 3/1/2026

Well-researched compound

Common Side Effects

• • Injection site redness or mild irritation (subcutaneous)
• • Mild nausea with oral administration (rare)
• • Transient lightheadedness reported anecdotally